View Older Stories View More Recent Stories

Aug 21, 2025 02:29PM Ionis Pharmaceuticals (IONS) PT Raised to $43 at Stifel
Aug 21, 2025 12:51PM BMO Capital Reiterates Market Perform Rating on Ionis Pharmaceuticals (IONS)
Aug 21, 2025 09:40AM Ionis Pharmaceuticals (IONS) Halted, News Pending
Aug 19, 2025 09:35AM Jefferies Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
Jul 31, 2025 06:43AM Ionis Pharmaceuticals (IONS) PT Raised to $65 at H.C. Wainwright
Jul 30, 2025 04:27PM Morgan Stanley Upgrades Ionis Pharmaceuticals (IONS) to Overweight
Jul 30, 2025 07:06AM Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 94c ; Offers Guidance
Jul 25, 2025 07:15AM Ionis drug TRYNGOLZA gets EU committee approval recommendation for rare disease
Jul 1, 2025 01:02AM Barclays Upgrades Ionis Pharmaceuticals (IONS) to Overweight
Jun 26, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
Jun 25, 2025 07:31AM Ionis Pharmaceuticals (IONS) announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Jun 25, 2025 07:31AM Biogen (BIIB) to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Jun 12, 2025 09:01AM Ionis Pharmaceuticals (IONS) Announces Retirement of Chief Development Officer
Jun 11, 2025 07:02AM Ionis Pharmaceuticals (IONS): First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
May 27, 2025 09:48AM Stifel Reiterates Hold Rating on Ionis Pharmaceuticals (IONS)
May 19, 2025 07:01AM Ionis Pharmaceuticals (IONS) announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
May 2, 2025 07:27AM Ionis Pharmaceuticals (IONS) PT Raised to $50 at H.C. Wainwright
Apr 30, 2025 07:05AM Ionis Pharmaceuticals (IONS) Tops Q1 EPS by 15c ; Offers Guidance
Apr 7, 2025 06:34AM H.C. Wainwright Starts Ionis Pharmaceuticals (IONS) at Buy
Mar 31, 2025 04:15AM Redburn-Atlantic Starts Ionis Pharmaceuticals (IONS) at Neutral
Mar 27, 2025 09:46AM UBS Reiterates Neutral Rating on Ionis Pharmaceuticals (IONS)
Mar 26, 2025 07:02AM Ionis Pharmaceuticals (IONS) expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Mar 12, 2025 08:35AM Oppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
Mar 11, 2025 06:13PM Ionis Pharmaceuticals (IONS) and Ono announce global license agreement
Mar 10, 2025 07:02AM Ionis Pharmaceuticals (IONS) Announces WAINZUA approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
Feb 21, 2025 06:35AM Ionis Pharmaceuticals (IONS) PT Lowered to $43 at Bernstein SocGen Group
Feb 20, 2025 07:03AM Ionis Pharmaceuticals (IONS): New positive donidalorsen data to be presented at AAAAI/WAO
Feb 20, 2025 05:50AM Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Raymond James
Feb 19, 2025 02:52PM Ionis Pharmaceuticals (IONS) PT Lowered to $38 at Stifel
Feb 19, 2025 07:05AM Ionis Pharmaceuticals (IONS) Tops Q4 EPS by 45c ; Offers Guidance
Jan 23, 2025 07:31AM Biogen (BIIB): FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Jan 6, 2025 02:00PM 7 top biotech picks for 2025 according to Wells Fargo
Dec 23, 2024 09:50AM Piper Sandler Reiterates Overweight Rating on Ionis Pharmaceuticals (IONS) Following FDA Approval
Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025
Dec 20, 2024 07:18AM Needham Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) on TRYNGOLZA approval
Dec 19, 2024 06:30PM Ionis Pharmaceuticals (IONS) FDA approves TRYNGOLZA for adults with familial chylomicronemia syndrome
Dec 19, 2024 04:50PM Ionis Pharmaceuticals' (IONS) tryngolza approved by FDA for adult patients with familial chylomicronemia syndrome
Dec 19, 2024 04:29PM Ionis Pharmaceuticals (IONS) Halted, News Pending
Dec 4, 2024 11:26AM Ionis Pharmaceuticals (IONS) Added to Raymond James Analyst Current Favorite List, Chart Industries (GTLS) Removed
Nov 6, 2024 07:07AM Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 17c
Nov 6, 2024 07:01AM Ionis Pharmaceuticals (IONS) Announces Pivotal Phase 3 Trial Design for ION582
Nov 4, 2024 09:45AM Ionis Pharmaceuticals (IONS) announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
Oct 21, 2024 05:57AM Ionis Pharmaceuticals (IONS) reports WAINZUA recommended for approval in the EU by CHMP
Oct 8, 2024 03:26PM Laidlaw Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
Oct 8, 2024 02:42PM TD Cowen Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
Oct 8, 2024 07:32AM Biogen (BIIB): New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
Oct 3, 2024 07:01AM Ionis Pharmaceuticals (IONS): New positive donidalorsen data to be presented at ACAAI
Oct 1, 2024 07:01AM Ionis Pharmaceuticals (IONS): Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Sep 26, 2024 06:23AM RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
Sep 10, 2024 06:21AM Ionis Pharmaceuticals (IONS) Prices 11.5M Share Offering at $43.50/sh
View More Recent Stories View Older Stories